Enphase Energy Inc vs IDEXX Laboratories, Inc. — how do they compare? Enphase Energy Inc trades at $32.63 (market cap $4.35B), while IDEXX Laboratories, Inc. trades at $516.84 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 9.3× Enphase Energy Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 5,068,595). Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| ENPH | IDXX | |
|---|---|---|
Market Cap | $4.35B | $40.43B |
Volume | 5,068,595 | 692,164 |
Sector | Energy | Health |
52-Week High | $72.33 | $766.68 |
52-Week Low | $26.12 | $504.70 |
Typical Hold Time | 72 Days | 46 Days |
Enterprise Value | $3.99B | $41.32B |
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.095, down 4.19% with bearish technical signals. The stock shows mixed fundamentals with revenue declining from $2.3B in 2023 to $1.47B in 2025, though net income margin improved to 11.68%. Recent earnings show two misses in the last three quarters. Analyst sentiment is divided with 42% buy ratings but a consensus price target of $42.90 suggesting 34% upside. The company continues innovation with IQ Meter Collar approvals and solid-state transformer development for AI data centers.
The stock faces headwinds from solar industry pressures and elevated borrowing costs, but maintains strong gross margins and product innovation. With current price near support at $32 and significant upside to analyst targets, ENPH presents a contrarian opportunity for investors believing in the long-term solar growth story despite near-term volatility.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →